Discovery may lead to new drugs to curb obesity, type 2 diabetes

(Medical Xpress)—An international study led by a researcher from The University of Western Australia for the Western Australian Institute for Medical Research (WAIMR) has produced exciting results that may lead to new drugs to treat obesity and reduce the incidence of Type 2 diabetes.

UWA Assistant Professor Vance Matthews led researchers in Melbourne, Texas and Japan to explore the effects of a protein on the surface of on conditions such as Type 2 diabetes and obesity.

Their results have appeared in the high-ranking immunology journal Immunology and Cell Biology, published by the .

Assistant Professor Matthews said the research was particularly important because had increased by 75% in the past 25 years, including an alarming increase in overweight and obese children. Insulin resistance correlated directly with obesity and could result in Type 2 diabetes, in which occurred in metabolically active body tissues.

"While my research looks at the growing problems of obesity and type 2 diabetes and how the inflammatory pathways are activated in our bodies, our discoveries also have far-reaching consequences for other diseases that involve inflammation," Assistant Professor Matthews said.

The study established that many parameters of the metabolic syndrome such as obesity and insulin resistance were significantly correlated with high levels of the metalloproteinase known as ADAM28 in .

The group explored interactions between the protein TNF-alpha – which is produced by numerous inflammatory cell types – and the metalloproteinase ADAM28. TNF-alpha is a well-known cytokine that promotes and increases the risk of Type 2 diabetes.

The study highlighted that the metalloproteinase ADAM28 may increase the release of TNF-alpha protein from the cell surface, and this effect may promote inflammation.

"Our project is very significant because it demonstrates for the first time the importance of ADAM28 in the metabolic syndrome, and further supports that metalloproteinase inhibition is a potential therapeutic target for anti-obesity agents," Assistant Professor Matthews said.

"This means that further down the track, drugs may become available to treat obesity, therefore reducing the incidence of type 2 diabetes."

add to favorites email to friend print save as pdf

Related Stories

Inflammation in body fat is not only pernicious

Mar 25, 2010

It has been a common opinion that inflammation in adipose tissue may cause insulin resistance, and thereby type 2 diabetes. However, recent research from the Swedish medical university Karolinska Institutet, published in ...

Insulin reduces inflammation caused by obesity

May 10, 2010

Recent decades have seen a huge increase in type 2 diabetes and cardiovascular disease. This is a result of people being less active and eating fattier diets, which can lead to obesity and, in turn, diabetes. In a thesis ...

Researchers identify key regulator of inflammatory response

Apr 12, 2012

(Medical Xpress) -- Researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a key role in regulating inflammatory response and homeostasis. These findings could help lead to the development ...

Recommended for you

Moms of food-allergic kids need dietician's support

5 hours ago

Discovering your child has a severe food allergy can be a terrible shock. Even more stressful can be determining what foods your child can and cannot eat, and constructing a new diet which might eliminate entire categories ...

Multiple allergic reactions traced to single protein

16 hours ago

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.